Medical benefit pharmaceutical policies for providers
See the latest updates to our medical benefit pharmaceutical policies.
MBP 127.0 Makena (hydroxyprogesterone caproate)
Makena (hydroxyprogesterone caproate) is a synthetic progestin indicated for reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. It is not intended for use in women with multiple gestations or other risk factors for preterm birth and is contraindicated in women with current or history of thrombosis or thromboembolic disorder, known or suspected breast cancer, other hormone-sensitive cancer, or history of these conditions, undiagnosed abnormal vaginal bleeding unrelated to pregnancy, cholestatic jaundice of pregnancy, liver tumors, benign or malignant, or active liver disease or uncontrolled hypertension
MBP 111.0 Marqibo (vincristine sulfate liposome injection)
Marqibo (vincristine sulfate liposome injection) is a sphiingomyelin/cholesterol liposome-encapsulated formulation of vincristine sulfate
MBP 175.0 Mepsevii (vestronidase alfa-vjbk)
Mepsevii (vestronidase alfa-vjbk) is a recombinant human beta-glucuronidase (GUS), which provides exogenous GUS enzyme for uptake into cellular lysosomes. Mannose-6-phosphate (M6P) residues on the oligosaccharide chains allow binding of the enzyme to cell surface receptors, leading to cellular uptake of the enzyme, targeting to lysosomes and subsequent catabolism of accumulated glycosaminoglycans (GAGs) in affected tissues.
MBP 130.0 Mircera (methoxy polyethylene glycol-epoetin beta)
Mircera (methoxy polyethylene glycol-epoetin beta) is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis and patients not on dialysis.
MBP 221.0 Monjuvi (tafasitamab-cxix)
Monjuvi (tafasitamab-cxix) is a humanized CD19-directed, Fc-modified monoclonal antibody that binds to CD19 antigen, which is expressed on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including diffuse large B-cell lymphoma. After binding to CD19, tafasitamab mediates B-cell lysis through apoptosis and immune effector mechanisms, including antibody-dependent cellular cytotoxicity and phagocytosis. Administering in combination with lenalidomide results in increased antibody-dependent cellular cytotoxicity activity compared to either agent alone.
New Policy 9/15/20
MBP 163.0 Mylotarg (gemtuzumab ozogamicin)
Mylotarg (gemtuzumab ozogamicin) is a humanized CD-33 directed monoclonal antibody-drug conjugate, which is composed of the IgG4 kappa antibody gemtuzumab linked to a cytotoxic calicheamicin derivative.
Learn more about Geisinger Health Plan.
Log in to NaviNet to access and view prior authorization information.
Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.
Terms and conditions
View GHP’s terms and conditions.
Questions? Contact us
If you have questions or need more information, contact Geisinger Health Plan.